# ModernaTX, Inc. clinical trials: 119 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 119 trials with ModernaTX, Inc. as lead sponsor, 18 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ModernaTX, Inc.: 119 rows for $5.95, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/modernatx-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 119
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 25 newest of 119, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919210 | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy... | ModernaTX, Inc. | Phase 1 | Not yet recruiting | Marburg Virus Disease (MVD) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919210) |
| November 5, 2026 | NCT07919197 | A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age | ModernaTX, Inc. | Phase 1 | Not yet recruiting | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919197) |
| October 20, 2026 | NCT07884175 | A Study of Updated mRNA Seasonal Influenza Vaccines | ModernaTX, Inc. | Phase 4 | Recruiting | Seasonal Influenza | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884175) |
| October 13, 2026 | NCT07870330 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children | ModernaTX, Inc. | Phase 1 | Recruiting | Seasonal Influenza | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870330) |
| October 7, 2026 | NCT07863635 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | ModernaTX, Inc. | Phase 4 | Recruiting | SARS-CoV-2 | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863635) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 13, 2026 | NCT07764237 | A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults | ModernaTX, Inc. | Phase 1 | Recruiting | Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764237) |
| July 30, 2026 | NCT07737717 | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in... | ModernaTX, Inc. | Phase 1 | Active not recruiting | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737717) |
| May 1, 2026 | NCT07561294 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70... | ModernaTX, Inc. | Phase 2 | Active not recruiting | Lyme Disease | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561294) |
| March 27, 2026 | NCT07496450 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | ModernaTX, Inc. | Phase 3 | Active not recruiting | Influenza | 4,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07496450) |
| March 18, 2026 | NCT07478952 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | ModernaTX, Inc. | Phase 1 | Recruiting | Epstein-Barr Virus | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478952) |
| December 5, 2025 | NCT07266558 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions... | ModernaTX, Inc. | Phase 4 | Active not recruiting | SARS-CoV-2 | 30,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07266558) |
| August 12, 2025 | NCT07117487 | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants... | ModernaTX, Inc. | Phase 3 | Completed | Respiratory Syncytial Virus | 507 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07117487) |
| August 11, 2025 | NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | ModernaTX, Inc. | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116616) |
| July 28, 2025 | NCT07089706 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations | ModernaTX, Inc. | Phase 4 | Completed | COVID-19 | 832 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07089706) |
| March 17, 2025 | NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | ModernaTX, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880549) |
| March 7, 2025 | NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to \<65... | ModernaTX, Inc. | Phase 2 | Completed | Influenza, SARS-CoV-2 | 1,320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06864143) |
| December 16, 2024 | NCT06735248 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | ModernaTX, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735248) |
| November 19, 2024 | NCT06694389 | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 \[COVID-19\] and Influenza) in Adults... | ModernaTX, Inc. | Phase 3 | Completed | COVID-19, Influenza | 2,457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06694389) |
| October 23, 2024 | NCT06655870 | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants | ModernaTX, Inc. | Phase 1 | Recruiting | Healthy Participants | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06655870) |
| October 10, 2024 | NCT06634797 | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | ModernaTX, Inc. | Phase 4 | Completed | Healthy Volunteers | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06634797) |
| September 19, 2024 | NCT06602024 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | ModernaTX, Inc. | Phase 3 | Completed | Seasonal Influenza | 40,805 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06602024) |
| September 19, 2024 | NCT06592794 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | ModernaTX, Inc. | Phase 3 | Active not recruiting | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | 37,864 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592794) |
| September 5, 2024 | NCT06585241 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | ModernaTX, Inc. | Phase 4 | Recruiting | SARS-CoV-2 | 1,144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585241) |
| July 18, 2024 | NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory... | ModernaTX, Inc. | Phase 2 | Completed | Influenza, SARS-CoV-2 | 931 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508320) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 31 |
| Phase 1/2 | 22 |
| Phase 2 | 18 |
| Phase 2/3 | 5 |
| Phase 3 | 18 |
| Phase 4 | 6 |
| Observational | 19 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 78 |
| Recruiting | 16 |
| Active not recruiting | 13 |
| Terminated | 6 |
| Withdrawn | 4 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Virus Diseases | 47 |
| COVID-19 | 34 |
| Coronavirus Infections | 30 |
| Influenza, Human | 22 |
| Cytomegalovirus Infections | 8 |
| Metabolism, Inborn Errors | 6 |
| Recurrence | 5 |
| Genetic Diseases, Inborn | 5 |
| DNA Virus Infections | 5 |
| Propionic Acidemia | 4 |
| Methylmalonic acidemia | 4 |
| Zika Virus Infection | 3 |
| Epstein-Barr Virus Infections | 3 |
| Metabolic Diseases | 3 |
| Multiple Myeloma | 2 |
| Herpes Simplex | 2 |
| Neoplasm Metastasis | 2 |
| Neoplasms | 2 |
| Myocarditis | 2 |
| Infectious Mononucleosis | 2 |
| Melanoma | 2 |
| Lymphoma | 2 |
| Lyme Disease | 2 |
| Amino Acid Metabolism, Inborn Errors | 2 |
| Acidosis | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
